E Fund Management Co. Ltd. Grows Position in Biohaven Ltd. (NYSE:BHVN)

E Fund Management Co. Ltd. raised its holdings in Biohaven Ltd. (NYSE:BHVN) by 58.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 11,883 shares of the company’s stock after acquiring an additional 4,407 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Biohaven were worth $412,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of BHVN. Vanguard Group Inc. raised its holdings in shares of Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock valued at $345,031,000 after buying an additional 4,650,702 shares in the last quarter. Stifel Financial Corp raised its holdings in shares of Biohaven by 7.9% during the 4th quarter. Stifel Financial Corp now owns 6,225,811 shares of the company’s stock valued at $266,465,000 after buying an additional 456,062 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Biohaven by 6.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,347,022 shares of the company’s stock valued at $183,050,000 after buying an additional 212,699 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Biohaven by 142.2% during the 4th quarter. Point72 Asset Management L.P. now owns 2,483,567 shares of the company’s stock valued at $106,297,000 after buying an additional 1,458,072 shares in the last quarter. Finally, Perceptive Advisors LLC raised its holdings in shares of Biohaven by 129.4% during the 4th quarter. Perceptive Advisors LLC now owns 1,725,047 shares of the company’s stock valued at $73,832,000 after buying an additional 973,227 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Insider Buying and Selling at Biohaven

In related news, Director John W. Childs acquired 28,400 shares of the stock in a transaction on Thursday, July 18th. The stock was acquired at an average price of $35.67 per share, for a total transaction of $1,013,028.00. Following the completion of the purchase, the director now owns 2,339,741 shares of the company’s stock, valued at $83,458,561.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.00% of the stock is owned by company insiders.

Biohaven Stock Performance

Shares of BHVN stock opened at $39.40 on Thursday. The firm has a market cap of $3.48 billion, a P/E ratio of -5.77 and a beta of 1.30. Biohaven Ltd. has a fifty-two week low of $16.45 and a fifty-two week high of $62.21. The business’s 50 day moving average price is $38.19 and its 200-day moving average price is $41.20.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Thursday, August 8th. The company reported ($3.64) earnings per share for the quarter, missing the consensus estimate of ($1.72) by ($1.92). As a group, equities analysts predict that Biohaven Ltd. will post -8.92 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $59.00 price objective on shares of Biohaven in a report on Thursday, May 30th. UBS Group decreased their price target on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. William Blair raised Biohaven to a “strong-buy” rating in a research note on Friday, August 30th. Jefferies Financial Group assumed coverage on Biohaven in a research note on Monday. They issued a “buy” rating and a $57.00 price target on the stock. Finally, Sanford C. Bernstein assumed coverage on Biohaven in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $55.00 price target on the stock. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Biohaven currently has a consensus rating of “Buy” and an average price target of $54.70.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.